Latest News

Wednesday, September 19, 2018

Exercise May Reduce Stroke Severity

In a study published in the online issue of Neurology (September 19, 2018), researchers have shown that people who exercise have lower stroke severity if and when they do experience stroke. In th…

Read the full story

Monday, September 17, 2018

Fremanezumab-vfrm Approved for Prevention of Migraine

The Food and Drug Administration (FDA) has approved fremanezumab-vfrm (Ajovy; Teva Pharmaceutical Industries, Jerusalem, Israel) for prevention of migraine in adults. Fremanezumab is administered…

Read the full story

Friday, September 14, 2018

Assessing Relative Neuropsychologic Performance in Patients with Parkinson’s Requires Comparison to Site-Specific Health Controls

In a study published online in the journal Movement Disorders (September 14, 2018), meta-analysis was used to examine the use of neuropsychologic testing to detect early cognitive impairments in peopl…

Read the full story

Thursday, September 13, 2018

Fingolimod Effective for Treating Pediatric Patients with Multiple Sclerosis

Complete results from landmark phase 3 PARADIGMS clinical trial (NCT01892722) were published in the New England Journal of Medicine (September 12, 2018). The PARADIGMS trial is the first-ever complete…

Read the full story

Wednesday, September 12, 2018

Cognitive Effects of Amyotrophic Lateral Sclerosis Increase as Disease Progresses

Although it is often referred to as a neurologic disease that attacks the body and not the mind, cognitive effects in amyotrophic lateral sclerosis (ALS) exist and have been reported in a study publis…

Read the full story

Wednesday, September 12, 2018

New Investigational Intranasal CGRP-Antagonist for Treatment of Migraine

An investigational drug application has been filed with the Food and Drug Administration (FDA) for BHV-3500 (Biohaven, New Haven, CT). This new compound is the first intranasal (IN) formulation of a s…

Read the full story

Tuesday, September 11, 2018

Pitolisant for Treatment of Patients with Narcolepsy has Long-Term Safety, Tolerability, and Durability of Effect

Long-term data for pitolisant (Harmony Biosciences, Plymouth Meeting PA), an investigational treatment for excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy, were presented …

Read the full story

Monday, September 10, 2018

FDA Approves of Oral Suspension of Riluzole for Patients With Amyotrophic Lateral Sclerosis

The Food and Drug Administration (FDA) has approved a new formulation of riluzole (Tiglutek; ITF Pharma, Berwyn, PA) for patients with amyotrophic lateral sclerosis (ALS). This is the first oral suspe…

Read the full story

Friday, September 07, 2018

Neuromodulation Effective for Dysphagia in Patients Who Experience Stroke and Reduces Length of Hospital Stay

Despite improvements in stroke care and patient outcomes, approximately 16% of patients who experience a stroke have a tracheostomy and ventilatory support. Dysphagia can significantly delay removal o…

Read the full story

Thursday, September 06, 2018

Phase 3 Results for Rimegepant for Treatment of Migraine Being Presented

Data from 2 phase 3 pivotal trials of rimegepant (Biohaven, New Haven, CT) for treatment of patients with migraine will be presented at the 17th Biennial Migraine Trust International Symposium (MTIS) …

Read the full story

Thursday, September 06, 2018

Hereditary Neuropathy Foundation Hosting Patient-Focused Drug Development Meeting September 28th, 2018

The Hereditary Neuropathy Foundation (HNF) is holding an externally-led, patient-focused drug development meeting for Charcot-Marie-Tooth disease (CMT) and inherited neuropathies (IN) on Friday, Septe…

Read the full story

Wednesday, September 05, 2018

Lower Extremity Radicular Pain Relieved With Tetrahydrocannabinol

In a small (n = 17 men), double-blind, placebo-controlled study using a counterbalanced within-subjects design, treatment of patients with chronic neuropathic pain with delta-9-tetrahydrocannibin…

Read the full story

Tuesday, September 04, 2018

New 7th Generation Mechanical Thrombectomy Device Launched by Penumbra

The Penumbra JET 7 and Penumbra JET D reperfusion catheters are no commercially available in the US, manufactured by and available from Penumbra (Alameda, CA). Both catheters are powered by the Penumb…

Read the full story

Tuesday, September 04, 2018

Phase 3 Trial of Low-Dose Fenfluramine for Lennox-Gastaut Syndrome Is Enrolling Patients

In a phase 2 open-label study of the orphan drug fenfluramine (ZX008; Zogenix, Emeryville, CA) for treatment of patients with Lennox-Gastaut Syndrome (LGS) refractory to treatment, the majority of pat…

Read the full story

Wednesday, August 29, 2018

Nusinersen Effective Treatment for Type 1 Spinal Muscle Atrophy Even When Given at Age 7 Months and Up

Nusinersen (Spinraza; Biogen, Cambridge, MA), a novel therapy approved by the Food and Drug Administration (FDA) for treatment of patients with spinal muscle atrophy (SMA). Results of an expanded acce…

Read the full story
Load More